20.102 Metakaryotic Stem Cells in Carcinogenesis: Origins and Cures


Class Info

Metakaryotic stem cells of organogenesis, wound healing, and the pathogenic lesions of cancers and atherosclerotic plaques. Metakaryotic cell resistance to x-ray- and chemo-therapies. Common drug treatment protocols lethal to metakaryotic cancer stem cells in vivo first clinical trial against pancreatic cancer. Application of a hypermutable/mutator stem cell model to the age-specific mortality from clonal diseases, and the expected responses to metakaryocidal drugs in attempted cure and prevention of tumors or atherosclerotic plaques. Students taking 20.215 responsible for de novo computer modeling.

This class has 7.01x, 18.02, 3.091, and 5.111 as prerequisites.

20.102 will be offered this semester (Fall 2018). It is instructed by E. V. Gostjeva and W. G. Thilly.

Lecture occurs 1:00 PM to 2:30 PM on Tuesdays and Thursdays in 16-220.

This class counts for a total of 12 credits.

You can find more information at the MIT + 20.102 - Google Search site.

MIT 20.102 Metakaryotic Stem Cells in Carcinogenesis: Origins and Cures Related Textbooks
MIT 20.102 Metakaryotic Stem Cells in Carcinogenesis: Origins and Cures On The Web

© Copyright 2015